autogene cevumeran
Term · Oncology and biomedicine · MLC-T-ONC-011313
An mRNA-based individualized, therapeutic cancer vaccine targeting an unspecified amount of tumor-associated antigens (TAAs) that are specifically expressed in the patient's cancer, with potential immunostimulatory and antineoplastic activities. Upon administration, autogene cevumeran is taken up and translated by antigen presenting cells (APCs) and the expressed protein is presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses against cancer cells expressing the TAA(s).
| Identifier | MLC-T-ONC-011313 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | personalized cancer vaccine RO7198457; PCV RO7198457 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-011313",
"term": "autogene cevumeran",
"field": "Oncology and biomedicine",
"definition": "An mRNA-based individualized, therapeutic cancer vaccine targeting an unspecified amount of tumor-associated antigens (TAAs) that are specifically expressed in the patient's cancer, with potential immunostimulatory and antineoplastic activities. Upon administration, autogene cevumeran is taken up and translated by antigen presenting cells (APCs) and the expressed protein is presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses against cancer cells expressing the TAA(s).",
"synonyms": [
"personalized cancer vaccine RO7198457",
"PCV RO7198457"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/autogene-cevumeran/"
}
Record 2,638 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.